JPWO2023120466A1 - - Google Patents

Info

Publication number
JPWO2023120466A1
JPWO2023120466A1 JP2023569427A JP2023569427A JPWO2023120466A1 JP WO2023120466 A1 JPWO2023120466 A1 JP WO2023120466A1 JP 2023569427 A JP2023569427 A JP 2023569427A JP 2023569427 A JP2023569427 A JP 2023569427A JP WO2023120466 A1 JPWO2023120466 A1 JP WO2023120466A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569427A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023120466A1 publication Critical patent/JPWO2023120466A1/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023569427A 2021-12-23 2022-12-19 Pending JPWO2023120466A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021209906 2021-12-23
PCT/JP2022/046640 WO2023120466A1 (ja) 2021-12-23 2022-12-19 アプレミラスト水和物含有製剤

Publications (1)

Publication Number Publication Date
JPWO2023120466A1 true JPWO2023120466A1 (de) 2023-06-29

Family

ID=86902426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569427A Pending JPWO2023120466A1 (de) 2021-12-23 2022-12-19

Country Status (3)

Country Link
JP (1) JPWO2023120466A1 (de)
TW (1) TW202325277A (de)
WO (1) WO2023120466A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US9387195B2 (en) * 2011-03-07 2016-07-12 Celgene Corporation Methods for treating diseases using isoindoline compounds
US9765026B2 (en) * 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
WO2019073477A1 (en) * 2017-10-10 2019-04-18 Mankind Pharma Ltd. PHARMACEUTICAL COMPOSITION OF APREMILAST WITH EXTENDED RELEASE
WO2019116386A1 (en) * 2017-12-12 2019-06-20 Alkem Laboratories Ltd. Oral pharmaceutical compositions of amorphous apremilast and process for preparing thereof

Also Published As

Publication number Publication date
WO2023120466A1 (ja) 2023-06-29
TW202325277A (zh) 2023-07-01

Similar Documents

Publication Publication Date Title
BR112023005462A2 (de)
BR112023012656A2 (de)
BR112021014123A2 (de)
BR112022009896A2 (de)
BR112023009656A2 (de)
BR112022024743A2 (de)
BR112023006729A2 (de)
BR102021018859A2 (de)
BR102021007058A2 (de)
BR112023008622A2 (de)
BR102020022030A2 (de)
JPWO2023120466A1 (de)
BR112023011738A2 (de)
BR112023016292A2 (de)
BR112023004146A2 (de)
BR112023011539A2 (de)
BR112023011610A2 (de)
BR112023008976A2 (de)
BR102021020147A2 (de)
BR102021018926A2 (de)
BR102021018167A2 (de)
BR102021017576A2 (de)
BR102021016837A2 (de)
BR102021016551A2 (de)
BR102021016375A2 (de)